G. Ruggiero

HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma.

C. Tripodo, N. Zaffaroni, M. Di Nicola, 2015, Blood.

HSPH1 Inhibition Down-regulates Bcl-6 and c-Myc and Hampers the Growth of Human Aggressive B-cell Non-Hodgkin Lymphoma

C. Tripodo, F. Braud, R. Zappasodi, 2015 .

HSPH 1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma

C. Tripodo, N. Zaffaroni, F. Braud, 2015 .

Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs

S. Pignata, P. Ricchi, R. Zarrilli, 2002, British Journal of Cancer.

Pleiotropic antitumor effects of the pan‐HDAC inhibitor ITF2357 against c‐Myc‐overexpressing human B‐cell non‐Hodgkin lymphomas

C. Croce, M. Iorio, N. Zaffaroni, 2014, International journal of cancer.

Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat

C. Tripodo, N. Zaffaroni, F. Zunino, 2018, Hematological oncology.

Pleiotropic antitumor effects of the pan‐HDAC inhibitor ITF2357 against c‐Myc‐overexpressing human B‐cell non‐Hodgkin lymphomas

C. Croce, M. Iorio, N. Zaffaroni, 2014, International journal of cancer.